Table 1.
Baseline characteristics
| Baseline characteristics | n (%) |
| Female sex | 19 (38) |
| Median age (years, IQR) | 36.4 (27.8–43.9) |
| Median age at diagnosis. (IQR) | 23.0 (19.8–35.0) |
| Median disease duration (IQR) | 4.5 (1.0–14.8) |
| Disease location (L1:L2:L3) | 4 (8): 11 (22): 35 (70) |
| +L4 | 4 (8) |
| +p | 18 (36) |
| Disease behaviour (B1: B2: B3) | 28 (56): 11 (22): 11 (22) |
| Prior surgery | 12 (24) |
| No prior biologics (0:1:2: 3) | 27 (54): 14 (28): 5 (10): 4 (8) |
| Biologicaltherapy initiated | |
| Adalimumab | 27 (54) |
| Infliximab | 4 (8) |
| Ustekinumab | 17 (34) |
| Vedolizumab | 1 (2) |
| Risankizumab | 1 (2) |
L1:L2:L3:L4—Montreal score for disease location (ileal: colonic, ileocolonic, upper gastrointestinal; +p—perianal disease; B1: B2: B3—Montreal score for disease behaviour—inflammatory, stricturing, penetrating.